开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Karen Bensted
For cancer patients, cancer immunotherapy is a promising and efficient treatment option. The use of cytokine, anticytokine, and antibody treatments to treat different types of cancer seems to be successful. The revelation that the human papillomavirus vaccination prevents cervical cancer has cleared the path for the creation of cancer vaccines for other types of virus-associated cancers, including Merkel cell carcinoma and liver cancer. In roughly 75% of patients with metastatic melanoma, adoptive cell treatment utilising tumor-infiltrating lymphocytes has been shown in clinical studies to cause tumour regression, raising the possibility that breast, lung, and kidney malignancies could soon be successfully treated with a similar approach. Additionally, it has been demonstrated that the treatment of cancer patients using genetically modified T cells transduced with genes encoding certain T cell receptors and chimeric antigen receptors is effective. According to this research, combination medicines are the best options for people seeking cancer immunotherapy.